Navigation Links
DermAvance Pharmaceuticals Announces Investment by Ben Franklin Technology Partners of Southeastern Pennsylvania
Date:5/1/2008

BERYWN, Pa., May 1 /PRNewswire/ -- DermAvance Pharmaceuticals, a privately held pharmaceutical company specializing in advanced technology applications for skin health and cosmetic dermatology, today announced it had received an investment from Ben Franklin Technology Partners of Southeastern Pennsylvania (BFTP/SEP). These funds are part of a Series B financing that will be used to complete the acquisition and commercialization of DA-007, a patent protected combination, second generation dermal filler.

Dermal fillers are used to reverse changes associated with aging and can reduce or eliminate wrinkles, raise scar depressions, enhance lips and replace soft-tissue volume loss, thus returning the dermis to its original youthful state. Current marketed fillers include market-leader Restylane, sold by Medicis Pharmaceutical, and Radiesse sold by Bioform.

"We were very pleased to be selected for an investment by Ben Franklin Technology Partners as a part of our Series B financing," says Keith Greathouse, DermAvance President and CEO. Partnering with Ben Franklin validates our technology and represents a significant step in our on-going financing plan for the company. We continue to speak with additional investors to augment this initial investment and expect to complete the Series B financing during the third quarter. The proceeds from the Series B financing will be used to in part to also prepare and file the registration package for U.S marketing approval and to plan for the commercial launch of DA-007.

Mr. Greathouse further stated that physicians and patients desire dermal fillers like DA-007 that are safe, non-animal derived, long-lasting, easy to administer, and cost effective. The facial regeneration market is emerging as a powerful force with the baby boomers coming of age, and the US dermal filler market is projected to reach $1 billion by 2012.

About DermAvance Pharmaceuticals, Inc.

DermAvance Pharmaceuticals, Inc. is a privately held dermatology pharmaceutical company focused on commercializing unique, and innovative anti- aging products to enhance the health and appearance of skin. The company was founded to meet the rapidly growing demand for facial skin rejuvenation products. DermAvance already has launched four product lines in this explosive anti-aging category including: Hyalogy (nano hyaluronic acid), Vivelif(R) (acetyl hexapeptide-3), Arnika Forte to reduce bruising, and SOYA. DermAvance markets and sells products directly to dermatologists and aesthetic physicians for in-office dispensing. http://www.DermAvance.com

About Ben Franklin Technology Partners of Southeastern Pennsylvania

Celebrating our 25th anniversary, BFTP/SEP is the region's catalyst for Stimulating Entrepreneurial Potential. Ben Franklin invests in innovative enterprises and creates commercialization pathways that generate wealth through science and technology. Part of a statewide network in Pennsylvania, BFTP/SEP provides entrepreneurs and established businesses with the Capital, Knowledge and Networks to compete in the global marketplace. BFTP/SEP has provided more than $130 million to grow more than 1,600 regional enterprises. BFTP/SEP is a founding partner of The Nanotechnology Institute(TM) (NTI), the Mid-Atlantic Nanotechnology Alliance (MANA(R)), Emerald Stage2 Venture Fund and the Minority Angel Investor Network. BFTP/SEP is part of the Commonwealth of Pennsylvania's Ben Franklin Technology Partnership. http://www.sep.benfranklin.org


'/>"/>
SOURCE DermAvance Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... -- The Texas Medical Center (TMC) and the ... announced the establishment of a new international BioBridge, a ... and the Texas Medical Center, the largest ... and the Texas Medical Center, with the support of ... health innovation ecosystem where emerging technologies can be developed, ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... both cellulose nanocrystals and cellulose nanofibrils. The composition claims are not limited ... also claims directed to combination with polymers, carbon fibers, graphene, and other materials. ...
(Date:12/5/2016)... December 5, 2016 According ... Market, by Products (Consumable, Instruments, Automated Cell Expansion ... and Stem Cell Research, Cancer, and Cell-Based Research), ... Banks) - Global Revenue, Trends, Growth, Share, Size ... Research, the global cell expansion market is expected ...
(Date:12/5/2016)... , Dec. 5, 2016  Eisai Inc. ... open-label two-year study of rufinamide, which were presented ... Epilepsy Society (AES) held from December 2-6 in ... final two-year safety, tolerability and cognitive data showed ... experienced similar safety and tolerability profiles, cognitive development ...
Breaking Biology Technology:
(Date:11/17/2016)... Nov. 17, 2016  AIC announces that it has just released a new white ... require high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or ...
(Date:11/14/2016)... Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), ... in challenging operating environments, announced its results for the ... a conference call to discuss these results on November ... Key Recent Accomplishments ... acquire Vislink Communication Systems. The purchase is expected to ...
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
Breaking Biology News(10 mins):